Journal for ImmunoTherapy of Cancer (Nov 2021)
894 The bispecific innate cell engagers AFM13 (CD30/CD16A) and AFM24 (EGFR/CD16A) increase the fraction of tumor target-responsive NK cells and boost serial killing
Abstract
No abstracts available.
Journal for ImmunoTherapy of Cancer (Nov 2021)